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AbstrAct
Objective to evaluate the effects of the t-cell costimulation 
blocker abatacept on anti-citrullinated protein antibodies 
(acPa) and rheumatoid factor (rF) in early rheumatoid arthritis 
(ra), and associations between changes in serological status 
and clinical response.
Methods Post hoc analysis of the phase iii agree study in 
methotrexate (MtX)-naïve patients with early ra and poor 
prognostic factors. Patients were randomised to abatacept 
(~10 mg/kg intravenously according to weight range) or placebo, 
plus MtX over 12 months followed by open-label abatacept 
plus MtX for 12 months. autoantibody titres were determined 
by eliSa at baseline and months 6 and 12 (double-blind phase). 
conversion to seronegative status and its association with 
clinical response were assessed at months 6 and 12.
Results abatacept plus MtX was associated with a greater 
decrease in acPa (but not rF) titres and higher rates of 
both acPa and rF conversion to seronegative status versus 
MtX alone. More patients converting to acPa seronegative 
status receiving abatacept plus MtX achieved remission 
according to Disease activity Score in 28 joints (c-reactive 
protein) or clinical Disease activity index than patients who 
remained acPa seropositive. Patients who converted to acPa 
seronegative status treated with abatacept plus MtX had a 
greater probability of achieving sustained remission and less 
radiographic progression than MtX alone or patients who 
remained acPa seropositive (either treatment).
Conclusions treatment with abatacept plus MtX was 
more likely to induce conversion to acPa/rF seronegative 
status in patients with early, erosive ra. conversion to acPa 
seronegative status was associated with better clinical and 
radiographic outcomes.
Trial registration number nct00122382
BaCkgROund
Rheumatoid arthritis (RA) is characterised by 
the production of autoantibodies, in particular 
rheumatoid factor (RF) and anti-citrullinated 
protein antibodies (ACPA).1 An estimated 
50%–70% of patients with RA present with 
Key messages
What is already known about this subject?
 ► in the agree study, patients with early, poor 
prognostic rheumatoid arthritis (ra) (erosions, 
highly active disease and seropositivity; 96.5% 
and 89.0% of patients were rheumatoid factor 
(rF) or anti-citrullinated protein antibody (acPa) 
seropositive), who were treated with abatacept 
in combination with methotrexate (MtX) for 12 
months achieved sustainable clinical, functional 
and radiographic benefits compared with patients 
treated with MtX alone.
What does this study add?
 ► in patients with early erosive ra, treatment with 
abatacept in combination with MtX led to a 
decrease in autoantibody titres, resulting in some 
patients undergoing conversion to acPa and rF 
seronegative status.
 ► conversion to acPa seronegative status was 
associated with a better treatment response, 
including higher rates of remission, an increased 
likelihood of achieving sustained remission and less 
radiographic progression.
How might this impact on clinical practice?
 ► these findings demonstrate that abatacept is 
an effective treatment in patients with early ra 
and that, by modulating t-cell responses at very 
early stages of the disease, it might be possible to 
alter underlying autoimmune processes with the 
potential for sustained drug-free remission.
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detectable ACPA titres, which are mainly of the IgG 
isotype and directed against post-translationally modified, 
citrullinated proteins.1–3 RF autoantibodies are primarily 
of the IgM isotype and directed against the Fc portion of 
the IgG isotype.1 RF and ACPA can be present without 
clinical symptoms for up to 10 years before the onset of 
RA,4–8 and as such make interesting early biomarkers for 
the disease. Both RF and ACPA are moderately corre-
lated with markers of inflammation, although the corre-
lation is greater for RF.9 ACPA is particularly sensitive 
for diagnosis and is a better prognostic indicator than 
RF for more severe RA and more rapid disease progres-
sion.1 3 In an early RA cohort, ACPA positivity was associ-
ated with a higher rate of joint destruction.10 Hecht et al 
demonstrated that both erosion number and size were 
highest in patients with concomitant ACPA and RF, and 
that their effects were additive.11 However, the presence 
of RF compared with its absence has been associated with 
higher disease activity in ACPA-positive patients,12 in line 
with the amplifying role of RF.13 In addition, RF- and 
ACPA-producing B cells are detectable at high levels in 
the synovial fluid of patients with RA, suggesting a direct 
contribution to synovial inflammation.14–17 
A recent report from Rombouts et al provides evidence 
for a role of T cells in ACPA production. The authors 
reported that, unlike other autoantibodies or non-reac-
tive IgG, ACPA IgG undergoes N-linked glycosylation of 
the Fab variable domains.18 The authors hypothesised 
that this glycosylation requires N-linked glycan consensus 
sites not present in the germline Fab domain sequence, 
and that these sites are introduced by somatic hyper-
mutation of the Ig variable region.18 Somatic hypermu-
tation occurs during the process of B-cell proliferation 
and differentiation that is regulated in part by activated T 
cells.3 In addition, the strong association between ACPA 
and human leucocyte antigen class II genes suggests a 
role for antigen-specific CD4+ T cells in the humoral 
immune response against citrullinated proteins.19
Abatacept is a soluble fusion protein consisting of the 
extracellular domain of human cytotoxic T-lymphocyte-as-
sociated antigen 4 linked to the modified Fc portion of 
human IgG1. Abatacept binds to CD80/CD86 on anti-
gen-presenting cells (APC), thereby blocking the inter-
action between CD80/CD86 and CD28 on T cells and 
inhibiting T-cell costimulation.20 21 In addition to peptide–
major histocompatibility complex recognition between 
APCs and T cells, costimulation is required for (naïve) T 
cells to become fully activated.1 Thus, if costimulation is 
blocked, T-cell-dependent B-cell differentiation into anti-
body-producing cells will likely be inhibited and antibody 
production impaired. Treatment with abatacept, through 
inhibition of T-cell costimulation, might therefore be 
expected to impact antibody production by B cells.
Abatacept is an effective treatment for both estab-
lished22 23 and early RA,24 25 and early treatment of RA 
has been shown to prevent disease progression and joint 
damage.24–27 The Abatacept trial to Gauge Remission and 
joint damage progression in methotrexate-naïve patients 
with Early Erosive rheumatoid arthritis (AGREE) was a 
2-year, phase III study with a 1-year, double-blind phase 
that assessed the efficacy, safety and tolerability of intra-
venous abatacept plus methotrexate (MTX) compared 
with placebo plus MTX, in MTX-naïve patients with 
early erosive RA and poor prognostic indicators.28 29 The 
primary results of the study demonstrated that treatment 
with abatacept plus MTX resulted in significantly greater 
and more sustained clinical and radiographic benefits 
than treatment with placebo plus MTX.
As abatacept’s mode of action includes inhibition of 
T-cell costimulation, it was hypothesised that patients 
who converted to a seronegative status might have a 
better clinical response to abatacept treatment than 
those who remained seropositive. This post hoc analysis 
of the AGREE study investigated the effects of abatacept 
in combination with MTX versus MTX alone on conver-
sion to seronegative status in ACPA-seropositive and 
RF-seropositive patients, and the relationship between 
seroconversion and clinical response.
MeTHOds
Patient population and study design
This was a post hoc analysis performed using data from 
the previously published AGREE study ( ClinicalTrials. gov 
identifier NCT00122382).28 29 Briefly, MTX-naïve patients 
with early RA (≤2 years since diagnosis) who were posi-
tive for RF and/or ACPA antibodies and had evidence 
of erosion were randomised 1:1 to receive abatacept 
(~10 mg/kg intravenously according to weight range) 
plus MTX or placebo plus MTX (hereafter referred to 
as ‘MTX alone’) over a 12-month double-blind period 
followed by open-label abatacept plus MTX for an addi-
tional 12 months.28 29 At baseline, all patients had high 
disease activity based on a tender joint count of ≥12, a 
swollen joint count of ≥10 and C-reactive protein (CRP) 
levels of ≥0.45 mg/dL.
determination of autoantibody titres
Serum samples to assess levels of RF and ACPA (by 
assessment of second-generation anti-cyclic citrullinated 
peptide-2 (CCP-2) antibodies) were taken at screening 
and at months 6 and 12 of the double-blind period and 
stored at –80°C. Anti-CCP-2 and RF (IgM isotype) anti-
body titres were determined by ELISA; for each patient, 
samples from different time points were analysed within 
the same assay. The cut-off for ACPA positivity was 5 AU/
mL and 15 IU/mL for RF positivity.
Outcome measures
ACPA and RF seroconversion was determined by 
comparing baseline antibody titres with titres at month 
6 or 12 of the double-blind phase. All patients were posi-
tive for RF and/or ACPA at baseline. Those with antibody 
titres below the cut-off value (ACPA 5 AU/mL; RF 15 IU/
mL) at month 6 or 12 were considered to have converted 
to a seronegative state.
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Disease activity was measured using the Disease 
Activity Score in 28 joints (CRP) (DAS28 (CRP)) or the 
Clinical Disease Activity Index (CDAI) at each study 
visit (screening, days 1, 15 and 29, and then every 28 
days) over 12 months. Remission was defined as DAS28 
(CRP) <2.6 or CDAI ≤2.8. First remission was defined as 
the first visit at which a patient met the requirements to 
achieve remission. Sustained first remission was defined 
as the first visit at which remission was reached and subse-
quently maintained for every visit up to month 12. The 
proportions of patients in remission at months 6 and 12 
and the cumulative probability of time to achieve first 
sustained DAS28 (CRP) remission (<2.6) over 12 months 
of treatment were determined.
Radiographs of the hands and feet were taken at 
screening, at months 6 and 12, and at the discontinua-
tion visit. The Genant-modiﬁed Sharp scoring method 
was used to assess the mean change from baseline in total 
Sharp score (TSS), and erosion and joint space narrowing 
(JSN) scores at months 6 and 12.
statistical analysis
In the original study, DAS28 (CRP)-defined remission was 
evaluated for the intent-to-treat population, with patients 
who discontinued considered to be non-responders. For 
the purpose of this report, all analyses were descriptive and 
were based on patients with DAS28 (CRP) and CDAI data 
available at baseline and months 6 and 12. The proportions 
of patients achieving remission according to DAS28 (CRP) 
and CDAI were analysed as point estimates with 95% CIs, 
estimated using classic binomial distribution. Cumulative 
probability of time to achieve first remission and sustained 
first remission according to DAS28 (CRP)-defined and 
CDAI criteria were evaluated based on Kaplan-Meier esti-
mates with 95% CIs. Patients who lost remission status were 
censored at the time of remission loss.
Mean changes from baseline in ACPA and RF titres were 
evaluated by analysis of covariance with treatment, base-
line score and disease status as covariates. The adjusted 
mean change, treatment differences and corresponding 
95% CIs were presented for months 6 and 12. In addi-
tion, the proportions of patients with conversion to ACPA 
and RF seronegative status at months 6 and 12 were anal-
ysed using point estimates with 95% CIs. The relationship 
between DAS28 (CRP) or CDAI remission and conver-
sion to ACPA or RF seronegative status was investigated 
by determining the proportions (95% CIs) of patients 
in remission by seroconversion status at months 6 and 
12. Mean changes from baseline in TSS, erosion and JSN 
scores were evaluated by analysis of covariance with treat-
ment, baseline score and disease status as covariates. The 
adjusted mean change, treatment differences and corre-
sponding 95% CIs were presented for months 6 and 12.
ResulTs
Patient population
In the original study, 509 patients were randomly assigned 
to receive abatacept plus MTX (n=256) or MTX alone 
(n=253).29 Of these, 459 patients completed year 1 and 
433 completed year 2.28 Demographic data and baseline 
characteristics have been previously published.28 29 All 
patients were positive for RF and/or ACPA at baseline. 
Of the 435 patients for whom ACPA status measurements 
were available at baseline and both months 6 and 12, 21 
(4.8%) were seronegative at month 6. Of the 461 patients 
for whom RF status measurements were available at base-
line and both months 6 and 12, 61 (13.2%) were seron-
egative at month 6. Baseline RF/ACPA mean (SD) for 
patients who received abatacept plus MTX versus MTX 
alone are given in figure 1.
Patient demographic data and baseline disease char-
acteristics by conversion to ACPA and RF seronegative 
status at month 6 are shown in table 1. Mean baseline 
DAS28 (CRP) in patients who seroconverted was 6.2 
in the abatacept plus MTX arm and 5.9 in the MTX 
alone arm. Patients who seroconverted had lower mean 
autoantibody levels at baseline compared with those 
who remained seropositive.
RF and aCPa titres following treatment with abatacept plus 
MTX or MTX alone
A decrease in autoantibody levels after 6 and 12 months, 
compared with baseline, was observed for all study 
groups. Mean ACPA and RF titres decreased from base-
line following treatment with abatacept plus MTX and 
MTX alone (figure 1). Whereas similar decreases in RF 
titres were observed in both treatment groups, treatment 
with abatacept plus MTX resulted in a larger decrease in 
ACPA titres versus MTX alone at both months 6 and 12 
(the 95% CI of the estimate of difference did not cross 0; 
figure 1).
For patients who converted to seronegative RF status 
at month 6, mean decreases from baseline in autoanti-
body levels were numerically larger following treatment 
with abatacept plus MTX versus MTX alone: respectively, 
mean changes in RF titres (IU/mL) were −50.4 vs −28.1 
at month 6, and −37.9 vs 3.2 at month 12; mean decreases 
in ACPA titres (AU/mL) were −116.0 vs −80.4 at month 
6, and −114.2 vs −39.9 at month 12. Similar findings 
were observed for patients who converted to seronega-
tive ACPA status at month 6: in the respective treatment 
groups, mean decreases from baseline in RF titres (IU/
mL) were −233.8 vs −131.5 at month 6, and −210.7 vs 
−150.2 at month 12, and mean decreases in ACPA titres 
(AU/mL) were −15.9 vs −6.0 at month 6, and −7.4 vs −6.5 
at month 12.
In contrast, among patients with persistent RF sero-
positivity at month 6, mean decreases from baseline in 
RF titres (IU/mL) were similar or numerically smaller 
with abatacept plus MTX versus MTX alone: −155.9 vs 
−159.1 at month 6, and −125.5 vs −171.8 at month 12, 
respectively. However, mean decreases in ACPA titres 
(AU/mL) for these patients were numerically larger with 
abatacept plus MTX versus MTX alone: −114.0 vs −47.8 at 
month 6, and −101.4 vs −13.0 at month 12, respectively. A 
similar pattern was seen for patients with persistent ACPA 
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seropositivity at month 6: with abatacept plus MTX versus 
MTX alone, respectively, mean decreases from baseline in 
RF titres (IU/mL) were −132.8 vs −157.3 at month 6, and 
−105.4 vs −165.3 at month 12, whereas mean decreases 
from baseline in ACPA titres (AU/mL) were −123.2 vs 
−57.8 at month 6, and −115.4 vs −19.4 at month 12.
Conversion to RF and aCPa seronegative status following 
treatment with abatacept plus MTX or MTX alone
A numerically larger proportion of patients converted to 
become RF or ACPA seronegative in response to treat-
ment with abatacept plus MTX versus MTX alone after 6 
and 12 months of treatment. At month 6, 17.0% (39/230) 
and 6.6% (15/227) of patients treated with abatacept 
plus MTX were RF and ACPA seronegative, respectively, 
compared with 9.5% (22/231) and 2.9% (6/208) of 
patients treated with MTX alone. Of the patients who were 
RF and ACPA seronegative at month 6, 17.9% (7/39) and 
13.3% (2/15) of those treated with abatacept plus MTX, 
and 18.2% (4/22) and 0% (0/6) of those treated with 
MTX alone, respectively, converted back to RF and ACPA 
seropositivity at month 12. At month 12, 18.5% (41/222) 
and 7.1% (15/212) of patients treated with abatacept 
plus MTX were RF and ACPA seronegative, respectively, 
compared with 14.6% (32/219) and 4.6% (9/198) of 
patients treated with MTX alone. The proportion of 
patients who converted to seronegative status was numer-
ically higher in the abatacept plus MTX treatment group 
than in the MTX alone group. Estimated differences 
(95% CIs) between treatment groups for conversion to 
RF and ACPA seronegative status were, respectively, 7.4% 
(0.8–14.1) and 3.7% (−0.8 to 8.2) at month 6, and 3.9% 
(−3.5 to 11.2) and 2.5% (−2.5 to 7.6) at month 12; only 
the estimate of difference (95% CI) for RF seroconver-
sion at month 6 did not cross 0 (figure 2), indicating that 
abatacept plus MTX may have a particularly prominent 
effect on RF seroconversion in early treatment.
Clinical and radiographic responses by conversion to 
seronegative status
In the abatacept plus MTX arm, a higher proportion 
of patients who converted to ACPA seronegative status 
achieved DAS28 (CRP) and CDAI remission at month 6 
compared with patients who were persistently ACPA sero-
positive (figure 3); the estimate of difference (95% CI) 
between converters to seronegative status and those who 
were persistently ACPA seropositive did not cross 0 for 
DAS28 (CRP)-defined remission at month 6. The propor-
tions (95% CIs) of patients who converted to ACPA 
seronegative status in the abatacept plus MTX arm and 
achieved DAS28 (CRP) and CDAI remission were 66.7% 
(42.8–90.5) and 46.7% (21.4–71.9) at month 6, and 
73.3% (51.0–95.7) and 46.7% (21.4–71.9) at month 12, 
respectively. In comparison, the proportions (95% CIs) 
of patients who were persistently ACPA seropositive and 
achieved DAS28 (CRP) and CDAI remission were 32.6% 
(26.2–38.9) and 20.8% (15.3–26.2) at month 6, and 48.7% 
(41.8–55.7) and 34.5% (27.9–41.2) at month 12, respec-
tively. A higher proportion of patients treated with abat-
acept plus MTX achieved DAS28 (CRP) or CDAI remis-
sion at months 6 and 12 compared with patients treated 
with MTX alone, regardless of whether they converted 
to seronegative status or not. In the MTX alone arm, 
the proportions (95% CIs) of patients achieving DAS28 
(CRP) and CDAI remission were 16.7% (0.0–46.5) and 
16.7% (0.0–46.5) at month 6, and 22.2% (0.0–49.4) and 
Figure 1 ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. Antibody 
titres were determined by ELISA at baseline and months 6 and 12. Baseline to month 6 and baseline to month 12 were 
carried out as separate analyses. Baseline means (SD) for: *abatacept+MTX versus MTX alone were 305 (469) vs 273 (342); 
**abatacept+MTX versus MTX alone were 305 (534) vs 272 (514); †abatacept+MTX versus MTX alone were 297 (426) vs 272 
(344); ‡abatacept+MTX versus MTX alone were 300 (537) vs 270 (524). ACPA titres were determined by assessment of second-
generation anti-cyclic citrullinated peptide-2 antibodies. ACPA, anti-citrullinated protein antibody; MTX, methotrexate; RA, 
rheumatoid arthritis; RF, rheumatoid factor.
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11.1% (0.0–31.6) at month 12, respectively, for patients 
who converted to ACPA seronegative status; and 21.8% 
(16.1–27.5) and 13.4% (8.7–18.1) at month 6, and 31.8% 
(25.1–38.4) and 20.1% (14.4–25.8) at month 12, respec-
tively, for patients who were persistently ACPA seroposi-
tive.
In the abatacept plus MTX treatment arm, numerically, 
there was a higher cumulative probability of reaching 
sustained first DAS28 (CRP)-defined remission among 
patients who converted to seronegative status compared 
with those who remained ACPA seropositive (figure 4). 
This difference was not observed among patients who 
received MTX alone. The proportion of patients who 
achieved sustained remission was consistently higher in 
the abatacept plus MTX treatment group versus MTX 
alone.
In both treatment groups, patients who underwent 
conversion to ACPA seronegative status showed less 
radiographic progression, as indicated by a smaller 
mean change from baseline in Genant-modified TSS, 
erosion and JSN scores at both month 6 and month 12, 
than patients who were persistently ACPA seropositive 
(figure 5). The estimate of difference (95% CI) between 
those who converted to seronegative status and those 
Figure 2 Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared 
with MTX alone. The proportion of patients with conversion to ACPA and RF seronegative status at months 6 and 12 and 
estimates of difference (95% CIs) between treatment groups are shown. Baseline to month 6 and baseline to month 12 were 
carried out as separate analyses. ACPA, anti-citrullinated protein antibody; MTX, methotrexate; N, total number of patients in 
respective analysis; n, number of patients that showed seroconversion; RA, rheumatoid arthritis; RF, rheumatoid factor.
Figure 3 Percentage of patients achieving remission by conversion to ACPA seronegative status. Antibody titres were 
determined by ELISA at baseline and months 6 and 12. Baseline to month 6 and baseline to month 12 were carried out as 
separate analyses. ACPA, anti-citrullinated protein antibody; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; 
DAS28, Disease Activity Score in 28 joints; diff, difference; MTX, methotrexate.
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who remained ACPA seropositive did not cross 0 only for 
TSS and erosion score in the abatacept plus MTX group 
at month 12. Differences in TSS and erosion scores, but 
not JSN scores, between converters to ACPA seronegative 
status and patients who were persistently ACPA seropos-
itive were larger among patients treated with abatacept 
plus MTX compared with those who received MTX 
alone.
Figure 4 Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA 
seronegative status. The cumulative probability of the time to achieve sustained first DAS28 (CRP) remission over 12 months 
in all patients treated with abatacept+MTX or MTX alone who underwent conversion to ACPA seronegative status compared 
with those who remained ACPA seropositive was evaluated based on estimated Kaplan-Meier curves. DAS28 (CRP) values 
were measured at all study visits (screening, days 1, 15 and 29, and then every 28 days) over 12 months. Antibody titres were 
determined by ELISA at baseline and months 6 and 12. Baseline to month 6 and baseline to month 12 were carried out as 
separate analyses. ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 
joints; MTX, methotrexate.
Figure 5 Radiographic outcomes in patients with early RA treated with (A) abatacept+MTX or (B) MTX alone by conversion to 
ACPA seronegative status. Antibody titres were determined by ELISA at baseline and months 6 and 12. Baseline to month 6 
and baseline to month 12 were carried out as separate analyses. Error bars represent 95% CIs. ACPA, anti-citrullinated protein 
antibody; diff, difference; JSN, joint space narrowing; MTX, methotrexate; RA, rheumatoid arthritis; TSS, total Sharp score.
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disCussiOn
In the AGREE study, patients with early, poor prognostic 
RA (erosions, highly active disease and seropositivity; 
96.5% and 89.0% of patients were RF or ACPA seropos-
itive), who were treated with abatacept plus MTX for 
12 months achieved sustainable clinical, functional and 
radiographic benefits compared with patients treated 
with MTX alone.28–30 The present post hoc analysis inves-
tigated the effect of abatacept in combination with MTX 
on RF and ACPA titres and the potential association 
between ACPA titres and clinical response. Combined 
treatment with abatacept and MTX led to a decrease 
in both RF and ACPA titres over 6 and 12 months, 
and conversion to RF and ACPA seronegative status in 
17.0%–18.5% and 6.6%–7.1% of patients, respectively. In 
those patients who converted to an autoantibody-nega-
tive status, the remission rates were higher than in those 
patients who did not seroconvert.
Abatacept inhibits T-cell costimulation by binding to 
CD80 and CD86 on APCs and blocking the binding of 
CD28 to CD80/86.20 B cells proliferate and differentiate 
into antibody-producing cells and switch from produc-
tion of IgM to IgG antibodies in response to stimuli from 
activated CD4+ T cells, for example, increased cytokine 
production.3 Thus, abatacept has the potential to indi-
rectly impact IgG isotype switching by inhibiting the 
costimulation and activation of T cells.
In the present study, after 6 and 12 months, a greater 
decrease in ACPA titres was observed with treatment with 
abatacept plus MTX compared with MTX alone in the 
overall population and by autoantibody status at month 
6. Conversely, mean decreases from baseline in RF titres 
were similar for the two treatment arms in the overall 
population, although there was some evidence of a treat-
ment effect in patients who converted to seronegative 
autoantibody status. In observational studies, reductions 
in RF as well as ACPA levels have been observed inde-
pendent of the use of biological agents and, indeed, in 
line with the present study, more frequent RF serocon-
version than ACPA seroconversion was reported. Reduc-
tions of both autoantibodies were observed in parallel 
with a reduction in disease activity.30 31 RF autoantibodies 
are primarily of the IgM isotype whereas ACPAs are 
primarily of the IgG isotype.1 B cells do not require T-cell 
help to produce IgM isotype antibodies. However, B-cell 
production of antibodies may change from one isotype 
to another through the processes of isotype switching 
and somatic hypermutation, which occurs during prolif-
eration and differentiation of B cells—in part regulated 
by activated T cells.3 Thus, the difference in effect of 
abatacept plus MTX compared with MTX alone on RF 
versus ACPA titres might be explained by this difference 
in autoantibody isotype and by the effect of monotherapy 
versus combination therapy on B-cell subsets. Treatment 
with abatacept plus MTX led to higher rates of conver-
sion to RF or ACPA seronegative status compared with 
treatment with MTX alone. Although abatacept inhibits 
T-cell activation, it also exerts anti-inflammatory effects 
in a T-cell-independent way,32 potentially through direct 
effects on B cells33 and macrophages.34
Current treatment strategies for RA employ a 
targeted approach aimed at reaching remission or low 
disease activity.35 36 The present analysis showed that 
in the abatacept plus MTX treatment arm the propor-
tion of patients who achieved DAS28 (CRP)-defined 
or CDAI-defined remission was higher among those 
who converted to seronegative status than those who 
remained persistently ACPA seropositive. Furthermore, 
the cumulative probability of achieving sustained first 
remission according to DAS28 (CRP)-defined criteria 
was higher among patients who converted to ACPA sero-
negative status treated with abatacept plus MTX than 
in those who remained ACPA seropositive. The small 
proportion of patients who were converters to ACPA 
seronegative status showed less radiographic progres-
sion over 12 months than patients who remained ACPA 
seropositive, regardless of treatment.
These findings are in line with previous studies of 
abatacept in patients with early RA. In the Abatacept 
study to Determine the effectiveness in preventing the 
development of rheumatoid arthritis in patients with 
Undifferentiated inflammatory arthritis and to evaluate 
Safety and Tolerability (ADJUST) trial,24 patients with 
undifferentiated arthritis or very early RA treated with 
abatacept for 6 months had delayed disease progres-
sion and prolonged inhibition of radiographic progres-
sion after cessation of treatment versus placebo, with a 
decrease from baseline in RF and ACPA titres.24 In the 
Assessing Very Early Rheumatoid arthritis Treatment 
(AVERT) study,25 compared with patients treated with 
MTX alone, patients treated with abatacept plus MTX 
showed significantly higher rates of remission and a 
higher number of patients achieved sustained drug-free 
remission after withdrawal of all therapies, as well as 
reduced inflammation and structural damage progres-
sion as assessed by changes in MRI scores (synovitis, 
osteitis and bone erosions).37 Furthermore, in a post 
hoc analysis of the AVERT study (MTX-naïve patients 
with early RA and highly active and erosive disease; 
100% and 95.2% of patients were ACPA and RF positive, 
respectively), a higher proportion of patients receiving 
abatacept plus MTX underwent conversion to ACPA 
seronegative status compared with those receiving 
MTX alone.38 In addition, a numerically higher propor-
tion of patients treated with abatacept plus MTX who 
became seronegative (ACPA IgM isotype) achieved 
clinical remission at month 12 compared with those 
who did not seroconvert, differences that were not 
seen for patients treated with MTX alone.38 However, 
a post hoc analysis of the Abatacept versus adaliMumab 
comParison in bioLogic-naïvE RA patients with back-
ground MTX (AMPLE) trial suggested that, despite a 
similar clinical response over 2 years between the two 
treatment groups, only abatacept plus MTX produced 
a continuous decline in the median levels of most 
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ACPAs beyond 1 year of treatment; an effect that was 
not sustained with adalimumab plus MTX.39
In the abatacept plus MTX group, a link between 
conversion to seronegative status and remission/inhibi-
tion of structural damage was noticeable, while this link 
was less obvious in the MTX group. Taken together, these 
data demonstrate that abatacept is an effective treatment 
in patients with early RA and that, by modulating T-cell 
responses at very early stages of the disease, it might be 
possible to alter underlying autoimmune processes; that 
is, slowing or halting disease progression with the poten-
tial for sustained drug-free remission.
There are limitations to post hoc analyses, which should 
be considered when interpreting the data presented 
here. The present post hoc analysis was a completers-only 
analysis, carried out on a relatively small subset of patients 
included in the original AGREE study who had complete 
data sets. Given the small numbers of patients with sero-
conversion, particularly those who converted to ACPA 
seronegative status, the findings should be interpreted 
with caution. The study was not designed or powered to 
detect differences between the treatment groups based 
on seroconversion status, and all analyses were descrip-
tive in nature. The findings would benefit from valida-
tion in a larger patient population.
COnClusiOn
In conclusion, the present post hoc analysis demonstrated 
that treatment with abatacept in combination with MTX 
led to a decrease in autoantibody titres, resulting in some 
patients undergoing conversion to RF and ACPA seroneg-
ative status. Conversion to ACPA seronegative status was 
associated with higher rates of remission, an increased 
likelihood of achieving sustained remission and less radi-
ographic progression.
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